These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1489946)

  • 1. Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX).
    Sallie RW; Tredger JM; Williams R
    Biopharm Drug Dispos; 1992 Oct; 13(7):555-8. PubMed ID: 1489946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of gender on the monoethylglycinexylidide test in normal subjects and liver donors.
    Oellerich M; Schütz E; Polzien F; Ringe B; Armstrong VW; Hartmann H; Burdelski M
    Ther Drug Monit; 1994 Jun; 16(3):225-31. PubMed ID: 8085276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans.
    Reichel C; Skodra T; Nacke A; Spengler U; Sauerbruch T
    Br J Clin Pharmacol; 1998 Dec; 46(6):535-9. PubMed ID: 9862241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of metabolic liver function and hepatic blood flow during cardiopulmonary bypass.
    Autschbach R; Falk V; Lange H; Oellerich M; Walther T; Mohr FW; Dalichau H
    Thorac Cardiovasc Surg; 1996 Apr; 44(2):76-80. PubMed ID: 8782332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors.
    Zotz RB; von Schönfeld J; Erhard J; Breuer N; Lange R; Beste M; Goebell H; Eigler FW
    Transplantation; 1997 Feb; 63(4):538-41. PubMed ID: 9047147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient.
    Potter JM; Hickman PE; Lynch SV; Henderson A; Wright M; Balderson G; Strong RW
    Transplantation; 1993 Dec; 56(6):1385-8. PubMed ID: 8279008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of the lidocaine-monoethylglycinexylidide test in the liver transplant recipient.
    Potter JM; Hickman PE; Henderson A; Balderson GA; Lynch SV; Strong RW
    Ther Drug Monit; 1996 Aug; 18(4):383-7. PubMed ID: 8857555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of the monoethylglycinexylidide test in pediatric liver transplant candidates.
    Burdelski M; Schütz E; Nolte-Buchholtz S; Armstrong VW; Oellerich M
    Ther Drug Monit; 1996 Aug; 18(4):378-82. PubMed ID: 8857554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lignocaine metabolite formation as a measure of pre-transplant liver function.
    Oellerich M; Burdelski M; Ringe B; Lamesch P; Gubernatis G; Bunzendahl H; Pichlmayr R; Herrmann H
    Lancet; 1989 Mar; 1(8639):640-2. PubMed ID: 2564460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide.
    McKindley DS; Boulet J; Sachdeva K; Wang P; Chichester C
    Shock; 2002 Mar; 17(3):199-204. PubMed ID: 11900338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quick, sensitive high-performance liquid chromatography assay for monoethylglycinexylidide and lignocaine in serum/plasma using solid-phase extraction.
    Chen Y; Potter JM; Ravenscroft PJ
    Ther Drug Monit; 1992 Aug; 14(4):317-21. PubMed ID: 1519306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
    Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MEGX test: a tool for the real-time assessment of hepatic function.
    Oellerich M; Armstrong VW
    Ther Drug Monit; 2001 Apr; 23(2):81-92. PubMed ID: 11294522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of liver disease and food on plasma MEGX concentrations.
    Pritchard-Davies R; Gross AS; Shenfield GM
    Br J Clin Pharmacol; 1994 Mar; 37(3):298-301. PubMed ID: 8198941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of monoethylglycinexylidide (MEGX) in clinically healthy dogs.
    Neumann S; Frenz M; Streit F; Oellerich M
    Can J Vet Res; 2011 Oct; 75(4):317-20. PubMed ID: 22468031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of age on plasma MEGX concentrations.
    Orlando R; Palatini P
    Br J Clin Pharmacol; 1997 Aug; 44(2):206-8. PubMed ID: 9278213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The monoethylglycinexylidide test for grading of liver cirrhosis.
    Fabris L; Jemmolo RM; Toffolo G; Paleari D; Viaggi S; Rigon M; Casagrande F; Lirussi F; Strazzabosco M; Cobelli C; Okolicsanyi L
    Aliment Pharmacol Ther; 1999 Jan; 13(1):67-75. PubMed ID: 9892881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycinexylidide.
    Oni G; Brown S; Burrus C; Grant L; Watkins J; Kenkel M; Barton F; Kenkel J
    Aesthet Surg J; 2010; 30(6):853-8. PubMed ID: 21131461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine.
    Isohanni MH; Neuvonen PJ; Palkama VJ; Olkkola KT
    Eur J Clin Pharmacol; 1998 Sep; 54(7):561-5. PubMed ID: 9832299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lidocaine elimination and monoethylglycinexylidide formation in patients with chronic hepatitis or cirrhosis.
    Testa R; Campo N; Caglieris S; Risso D; Alvarez S; Arzani L; Giannini E; Lantieri PB; Celle G
    Hepatogastroenterology; 1998; 45(19):154-9. PubMed ID: 9496506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.